Presentation is loading. Please wait.

Presentation is loading. Please wait.

Khashayar Salartash, MD, Mark D

Similar presentations


Presentation on theme: "Khashayar Salartash, MD, Mark D"— Presentation transcript:

1 Oral low–molecular weight heparin and delivery agent prevents jugular venous thrombosis in the rat 
Khashayar Salartash, MD, Mark D. Gonze, MD, Andrea Leone-Bay, PhD, Robert Baughman, PhD, W.Charles Sternbergh, MD, Samuel R. Money, MD  Journal of Vascular Surgery  Volume 30, Issue 3, Pages (September 1999) DOI: /S (99) Copyright © 1999 Society for Vascular Surgery and International Society for Cardiovascular Surgery, North American Chapter Terms and Conditions

2 Fig. 1 Jugular vein was examined for presence of thrombus while in situ. Animals in groups 4 and 5 displayed statistically significant decreased amount of visible thrombus (*P < .05, with analysis of variance) as compared with groups 1, 2, and 3. No visible difference was noted between groups 4 and 5 (#P = NS). LMWH, Low–molecular weight heparin; SNAD, sodium N-[10-(2-hydroxybenzoyl)amino] decanoate; SQ, subcutaneous. Journal of Vascular Surgery  , DOI: ( /S (99) ) Copyright © 1999 Society for Vascular Surgery and International Society for Cardiovascular Surgery, North American Chapter Terms and Conditions

3 Fig. 2 Thrombus was extracted from excised jugular vein. Animals in groups 4 and 5 displayed quantitatively less thrombus (*P < .05, with analysis of variance) compared with groups 1, 2, and 3. No significant difference in weight of extracted thrombus was noted between groups 4 and 5 (#P = NS). LMWH, Low–molecular weight heparin; SNAD, sodium N-[10-(2-hydroxybenzoyl)amino] decanoate; SQ, subcutaneous. Journal of Vascular Surgery  , DOI: ( /S (99) ) Copyright © 1999 Society for Vascular Surgery and International Society for Cardiovascular Surgery, North American Chapter Terms and Conditions

4 Fig. 3 Anti-factor Xa levels were measured and depicted in IU/mL. All three preparations of low–molecular weight heparin (LMWH) caused statistically significant increases in levels of anti-factor Xa above baseline (*P < .05). Oral administration of LMWH with its carrier sodium N-[10-(2-hydroxybenzoyl)amino]decanoate (SNAD) caused statistically significant elevation in anti-factor Xa levels (#P < .05) when compared with LMWH alone. Subcutaneous (SQ) administration of LMWH at one third of oral dose causes dramatic elevation of anti-factor Xa levels. Journal of Vascular Surgery  , DOI: ( /S (99) ) Copyright © 1999 Society for Vascular Surgery and International Society for Cardiovascular Surgery, North American Chapter Terms and Conditions


Download ppt "Khashayar Salartash, MD, Mark D"

Similar presentations


Ads by Google